about
Preclinical and Clinical Studies on Antioxidative, Antihypertensive and Cardioprotective Effect of Marine Proteins and Peptides-A ReviewEvidence and evidence gaps of medical treatment of non-tumorous diseases of the head and neckInteractive Effect of the KCNJ11 Ile337Val Polymorphism and Cigarette Smoking on the Antihypertensive Response to Irbesartan in Chinese Hypertensive Patients.Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor.Increased renal vasodilator prostanoids prevent hypertension in mice lacking the angiotensin subtype-2 receptorEnd-stage renal failure after irbesartan prescription in a diabetic patient with previously stable chronic renal insufficiency.New competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure.The effect of angiotensin II on intracellular pH is mediated by AT(1) receptor translocation.Practical considerations of the pharmacology of angiotensin receptor blockers.Postinfarction left ventricular remodelling: where are the theories and trials leading us?Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists.The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema.Renin-angiotensin system regulates neurodegeneration in a mouse model of normal tension glaucoma.Inhibitory effects of olmesartan on catecholamine secretion from the perfused rat adrenal medullaNew advances in the pharmacological management of chronic heart failure.Combination therapy with an angiotensin converting enzyme inhibitor and an angiotensin-II receptor antagonist for refractory essential hypertension.Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.Angiotensin II modulates mouse skeletal muscle resting conductance to chloride and potassium ions and calcium homeostasis via the AT1 receptor and NADPH oxidaseAngiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease.Identification of calcium-modulating cyclophilin ligand (CAML) as transducer of angiotensin II-mediated nuclear factor of activated T cells (NFAT) activation.Therapeutic potential of angiotensin II receptor antagonists.Angiotensin II receptor blockers for the treatment of hypertension.Pharmacotherapy of hypertension in patients with diabetes mellitus.Discovery of GPCR ligands for probing signal transduction pathways.Angiotensin II as a cardiovascular risk factor.Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions.Stress-sensitive neurosignalling in depression: an integrated network biology approach to candidate gene selection for genetic association analysis.Angiotensin II Type 1 receptor antagonists in chronic heart failure.Nonallergic angioedema: role of bradykinin.Strategies to meet lower blood pressure goals with a new standard in angiotensin II receptor blockade.Amlodipine versus Angiotensin-receptor blockers for nonhypertension indications.Determination of single-nucleotide polymorphisms by real-time pyrophosphate DNA sequencing.The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols.Angiotensinergic stimulation of vascular endothelium in mice causes hypotension, bradycardia, and attenuated angiotensin response.Method Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry for Angiotensin-II in Human Plasma: Application to Study Interaction Between Atorvastatin & Olmesartan Drug CombinationThe effect of antihypertensive drugs on endothelial function as assessed by flow-mediated vasodilation in hypertensive patients.Angiotensin type 1a receptor deficiency decreases amyloid β-protein generation and ameliorates brain amyloid pathology.Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall.Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.Dose-modifying factor for captopril for mitigation of radiation injury to normal lung
P2860
Q28067396-A8B8150A-992E-45B3-AE40-55431F456268Q28070005-DA20A9CB-99B3-4612-9202-1B9F92F65921Q30278813-929C3D4E-71C3-4933-BA77-B6B6B1214A93Q30304009-8F8DEC3C-9B4D-474C-8E2C-75FBB97CC85AQ30304142-C1315D15-F9CD-47BB-A811-A7E62ECE7502Q31647703-C80705F1-9007-4CEA-87B2-2808BD548FF0Q31989723-0A057983-25F9-417F-8CF0-12D916AFE5C1Q33330598-5D96B6D4-F45C-44E8-9EF1-F21E46B76B4DQ33650699-2897ADA2-64BB-4E67-AC46-61CA7225B1E2Q33807515-E99A2A3D-2E3A-41C9-84BE-1D35713DAAC8Q33839744-FBD9E934-D531-4599-93F3-41CC8034027BQ33852836-639FEEA3-A129-470C-900A-041FAFDE1EAEQ34007779-E2DA828C-66B3-4766-BBF2-8326C45E817CQ34104490-96370759-4E80-4187-9E1D-66880A420244Q34182249-4138BDB9-8D15-403A-A6EA-CE815EE25782Q34188314-E652F4D7-2A73-4323-A1A9-2398E55B56E1Q34228796-21E77D15-C200-4D90-BF95-3024B0BC833DQ34295366-72D45BB9-6AB9-4FBA-B8DB-6DD0928881ACQ34309152-E0250EEA-3AA2-456F-B670-ACE3EED9201EQ34387658-13DD57B8-9263-41C6-AE09-F9AC1DBF8B45Q34481715-94910709-F0C3-4959-A038-025F326791D5Q34515476-544D3ABB-AE9B-4FD3-97FB-3EF728816160Q34515483-0B91D916-9F02-45E2-A02F-45FA25C34395Q34582707-2AF09469-87AE-4919-AFAE-D2438DC66C27Q34610027-4033908B-2401-49A8-AFB2-4A1D0530EDCBQ34614447-6C6FE0FA-73A1-4542-9F4F-E6CA6819883BQ34618962-86C27B35-D485-4054-A58C-898F3743D93AQ34628700-9B890638-9656-4F82-AF21-E4FABA2F901BQ34647610-F60BB465-6344-42F2-A0BC-FBEC0258FA4BQ34970370-7E906DAE-7940-4FD0-9DB0-1215CEF146F7Q34979673-EFB9AC62-7767-4C04-95F0-FA678EE4BE5AQ35028450-A104CCE4-6973-4B48-BF36-CBC8FC6715D4Q35135132-6A1E2FFE-DACC-41BF-925F-B9414833E18CQ35539793-C636EB32-7122-474E-A4EC-7BAD0C9911D1Q35747133-D4576E19-2369-411D-9B76-375B8BC5D03BQ35830347-D9C41BAA-21A6-4137-AF79-0749185DA76DQ35830493-C25285D6-74A8-4890-98B8-C3D344018552Q35855619-1DCBAE4E-160F-4AE6-8E3F-069153B25E27Q36051199-096634BC-3F69-4A90-BBBF-576D90A67483Q36086165-CBFA0D84-154D-495A-9CD3-85936A092B9A
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Angiotensin receptors and their antagonists.
@en
type
label
Angiotensin receptors and their antagonists.
@en
prefLabel
Angiotensin receptors and their antagonists.
@en
P2093
P1476
Angiotensin receptors and their antagonists.
@en
P2093
Elliott ME
Goodfriend TL
P304
P356
10.1056/NEJM199606203342507
P407
P577
1996-06-01T00:00:00Z